Company: NDRA
Filing Date: 2025-10-15
Form Type: 8-K/A
Source: 0001654954-25-011825
Chunk: 3

Company: ENDRA Life Sciences Inc.
Filing Date: 2025-10-15
Form: 8-K/A
Chunk 3
---
 pursuant to Section 4(a)(2) thereof and/or Rule 506(c) of Regulation D promulgated thereunder, and applicable state securities laws.

| 2 |

Registration Rights Agreement

In connection with entering into the Securities Purchase Agreement, on the Closing Date, the Company and the Purchasers will enter into a Registration Rights Agreement (the “Registration Rights Agreement”) pursuant to which the Company will agree to file a registration statement with the U.S. Securities and Exchange Commission (the “SEC”) within thirty (30) days of the Closing Date registering, as applicable, the resale of the Shares, the Prefunded Warrant Shares and the Warrant Shares.

The foregoing description of the Registration Rights Agreement does not purport to be complete and is qualified in its entirety by the full text of such document, which is filed herewith as Exhibit 10.2.

Investment Management Agreement

In connection with the Company’s DAT strategy, the Company entered into an Amended and Restated Investment Management Agreement (the “Investment Management Agreement”) with Arca Investment Management, LLC, a limited liability company (“Arca”), pursuant to which the Company engaged Arca to provide asset management services in accordance with the investment strategy and investment objectives, policies, guidelines and restrictions as agreed to from time to time by the Company and Arca.

The assets subject to the Investment Management Agreement will initially consist of approximately $3.5 million of proceeds from the Offering. Arca will have discretion to manage funds allocated to the Company’s DAT strategy, focusing on decentralized finance, including, without limitation, by purchasing $HYPE, the native digital asset of the Hyperliquid network, directly or indirectly through the use of derivative instruments.

Pursuant to the Investment Management Agreement, the Company will pay Arca a fee ranging from 1.25% to 1.75% of assets under management, based on the amount of such assets under management (“AUM”), per annum and payable monthly. Additionally, the Company will pay Arca a performance fee ranging from 10% to 15% of the net total return of the underlying assets, based on the amount of such assets under management. In connection with the closing of the Offering and pursuant to the Investment Management Agreement, the Company issued to Arca warrants to purchase an aggregate of 400,000 shares of Common Stock (the “Advisory Warrants”). Advisory Warrants in respect of 100,000 shares are exercisable immediately for an exercise price equal to $6.95, or 110